Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-γ ELISPOT assay

European Journal of Immunology

Volumn 39, Issue 4, 2009, Pages 975-985

  Winstone, Nicola ^a   Guimarães Walker, Ana ^a   Roberts, Joanna ^a   Brown, Denise ^a   Loach, Vanessa ^a   Goonetilleke, Nilu ^a   Hanke, Tomáš ^a   McMichael, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical trial; DNA MVA accines; HIV 1; Memory T cells

Indexed keywords

DNA MODIFIED VACCINIA VIRUS ANKARA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 13; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MODIFIED VACCINIA VIRUS ANKARA VACCINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PEPTIDE; PTHR.HIVA;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NORMAL HUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; VACCINATION; AMINO ACID SEQUENCE; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CELL LINE; CULTURE TECHNIQUE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS;

AIDS VACCINES; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE; CYTOKINES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MOLECULAR SEQUENCE DATA; PEPTIDES; VACCINES, DNA;

EID: 65449172097     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200839167     Document Type: Article

References (52)

1. McMichael, A. J., HIV vaccines. Annu. Rev. Immunol. 2006. 24: 227-255.
2. Bourgeois, C., Rocha, B. and Tanchot, C., A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002. 297: 2060-2063.
3. Sun, J. C. and Bevan, M. J., Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003. 300: 339-342.
4. Dooms, H. and Abbas, A. K., Control of CD4+ T-cell memory by cytokines and costimulators. Immunol. Rev. 2006. 211: 23-38.
5. Brenchley, J. M., Schacker, T. W., Ruff, L. E., Price, D. A., Taylor, J. H., Beilman, G. J., Nguyen, P. L. et al., CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004. 200: 749-759.
6. Mattapallil, J. J., Douek, D. C., Hill, B., Nishimura, Y., Martin, M. and Roederer, M., Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005. 434: 1093-1097.
7. Hanke, T., Blanchard, T. J., Schneider, J., Hannan, C. M., Becker, M., Gilbert, S. C., Hill, A. V. S. et al., Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998. 16: 439-445.
8. Hanke, T. and McMichael, A. J., Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 2000. 6: 951-955.
9. Guimaraes-Walker, A., Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., Barin, B. et al., Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008 26: 6671-6677.
10. Hanke, T., Goonetilleke, N., McMichael, A. J. and Dorrell, L., Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J. Gen. Virol. 2007. 88: 1-12.
11. Jaoko, W., Nakwagala, F. N., Anzala, O., Manyonyi, G. O., Birungi, J., Nanvubya, A., Bashir, F. et al., Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008. 26: 2788-2795.
12. Mwau, M., Cebere, I., Sutton, J., Chikoti, P., Winstone, N., Wee, E. G.-T., Beattie, T. et al., An HIV-1 clade A vaccine in clinical trials: Stimulation of HIV-specific T cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 2004. 85: 911-919.
13. Peters, B. S., Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J. et al., Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine 2007. 25: 2120-2127.
14. Goonetilleke, N., Moore, S., Dally, L., Winstone, N., Mahmoud, N., Cebere, I., Pinheiro, S. et al., Prime-boost vaccination with recombinant DNA and MVA expressing HIV-1 Clade A gag and immunodominant CTL epitopes induces multi-functional HIV-1-specific T cells in healthy subjects. J. Virol. 2006. 80: 4717-4728.
15. Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Bornstein, E., Asher, T. E. et al., Superior control of HIV-1 replication by CD81 T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 2007. 204: 2473-2485.
16. Excler, J. L., Rida, W., Priddy, F., Fast, P. and Koff, W., A strategy for accelerating the development of preventive AIDS vaccines. AIDS 2007. 21: 2259-2263.
17. Hanke, T., STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines 2008. 7: 303-309.
18. Mwau, M., McMichael, A. J. and Hanke, T., Design and validation of an ELISPOT assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retroviruses 2002. 18: 611-618.
19. Kaufmann, D. E., Bailey, P. M., Sidney, J., Wagner, B., Norris, P. J., Johnston, M. N., Cosimi, L. A. et al., Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 2004. 78: 4463-4477.
20. Boritz, E., Palmer, B. E., Livingston, B., Sette, A. andWilson, C. C., Diverse repertoire of HIV-1 p24-specific, IFN-gamma-producing CD4+ T cell clones following immune reconstitution on highly active antiretroviral therapy. J. Immunol. 2003. 170: 1106-1116.
21. Lotti, B., Wendland, T., Furrer, H., Yawalkar, N., von Greyerz, S., Schnyder, K., Brandes, M. et al., Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. J. Clin. Immunol. 2002. 22: 253-262.
22. + T cells. Blood 2006. 107: 4781-4789.
23. Fujiwara, M. and Takiguchi, M., HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages. Blood 2007. 109: 4832-4838.
24. Stittelaar, K. J., Gruters, R. A., Schutten, M., van Baalen, C. A., van Amerongen, G., Cranage, M., Liljestrom, P. et al., Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002. 20: 2921-2927.
25. Yang, H., Dong, T., Turnbull, E., Ranasinghe, S., Ondondo, B., Goonetilleke, N., Winstone, N. et al., Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy. J. Immunol. 2007. 179: 597-606.
26. Yang, O. O., Kalams, S. A., Trocha, A., Cao, H., Luster, A., Johnson, R. P. and Walker, B. D., Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 1997. 71: 3120-3128.
27. Douek, D. C., Brenchley, J. M., Betts, M. R., Ambrozak, D. R., Hill, B. J., Okamoto, Y., Casazza, J. P. et al., HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002. 417: 95-98.
28. Kalams, S. A. and Walker, B. D., The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 1998. 188: 2199-2204.
29. Rosenberg, E. S., Billingsley, J.M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams, S. A. and Walker, B. D., Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997. 278: 1447-1450.
30. Im, E. J., Saubi, N., Virgili, G., Sander, C., Teoh, D., Gatell, J. M., McShane, H. et al., Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J. Virol. 2007. 81: 9408-9418.
31. Im, E.-J., di Gleria, K., McMichael, A. J. and Hanke, T., Induction of longlasting multi-specific CD8+ T cells by a 4-component DNA-MVA/HIVARENTA candidate HIV-1 vaccine in rhesus macaques. Eur. J. Immunol. 2006. 36: 2574-2584.
32. Nkolola, J. P., Wee, E. G.-T., Im, E.-J., Jewell, C. P., Chen, N., Xu, X.-N., McMichael, A. J. et al., Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 2004. 11: 1068-1080.
33. Wee, E. G.-T., Patel, S., McMichael, A. J. and Hanke, T., A DNA/ MVA-based candidate HIV vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 2002. 83: 75-80.
34. Im, E. J. and Hanke, T., Short communication: Preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice. AIDS Res. Hum. Retroviruses 2007. 23: 857-862.
35. Moorthy, V. S., Pinder, M., Reece, W. H., Watkins, K., Atabani, S., Hannan, C., Bojang, K. et al., Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J. Infect. Dis. 2003. 188: 1239-1244.
36. Vuola, J. M., Keating, S.,Webster, D. P., Berthoud, T., Dunachie, S., Gilbert, S. C. and Hill, A. V., Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 2005. 174: 449-455.
37. Dorrell, L., Yang, H., Ondondo, B., Dong, T., di Gleria, K., Suttill, A., Conlon, C. et al., Expansion and diversification of HIV-1-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J. Virol. 2006. 80: 4705-4716.
38. Hanke, T., McMichael, A. J., Dennise, M. J., Sharpe, S. A., Powell, L. A. J., McLoughlin, L. and Crome, S. J., Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 2005. 23: 1507-1514.
39. Hanke, T., McMichael, A. J., Samuel, R. S., Powell, L. A. J., McLoughlin, L., Crome, S. J. and Edlin, A., Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 2002. 21: 109-115.
40. Tatsis, N., Fitzgerald, J. C., Reyes-Sandoval, A., Harris-McCoy, K. C., Hensley, S. E., Zhou, D., Lin, S.W. et al., Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007. 110: 1916-1923.
41. Pahar, B., Li, J. and McChesney, M. B., Detection of T cell memory to measles virus in experimentally infected rhesus macaques by cytokine flow cytometry. J. Immunol. Methods 2005. 304: 174-183.
42. Godkin, A. J., Thomas, H. C. and Openshaw, P. J., Evolution of epitopespecific memory CD4(+) T cells after clearance of hepatitis C virus. J. Immunol. 2002. 169: 2210-2214.
43. Combadiere, B., Boissonnas, A., Carcelain, G., Lefranc, E., Samri, A., Bricaire, F., Debre, P. et al., Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J. Exp. Med. 2004. 199: 1585-1593.
44. Hammarlund, E., Lewis, M. W., Hansen, S. G., Strelow, L. I., Nelson, J. A., Sexton, G. J., Hanifin, J. M. et al., Duration of antiviral immunity after smallpox vaccination. Nat. Med. 2003. 9: 1131-1137.
45. Honeyborne, I., Prendergast, A., Pereyra, F., Leslie, A., Crawford, H., Payne, R., Reddy, S. et al., Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J. Virol. 2007. 81: 3667-3672.
46. Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S. et al., CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007. 13: 46-53.
47. Rolland, M., Heckerman, D., Deng, W., Rousseau, C. M., Coovadia, H., Bishop, K., Goulder, P. J. et al., Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 2008. 3: E1424.
48. Ferrari, G., Kostyu, D. D., Cox, J., Dawson, D. V., Flores, J., Weinhold, K. J. and Osmanov, S., Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res. Hum. Retroviruses 2000. 16: 1433-1443.
49. Letourneau, S., Im, E.-J.,Mashishi, T., Brereton, C., Bridgeman, A., Yang, H., Dorrell, L. et al., Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007. 2: e984.
50. Promadej, N., Costello, C., Wernett, M. M., Kulkarni, P. S., Robison, V. A., Nelson, K. E., Hodge, T. W. et al., Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIVseronegative women highly exposed to a single HIV-infected partner. J. Infect. Dis. 2003. 187: 1053-1063.
51. Wilson, C. C., McKinney, D., Anders, M., MaWhinney, S., Forster, J., Crimi, C., Southwood, S. et al., Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J. Immunol. 2003. 171: 5611-5623.
52. Meyer, H., Sutter, G. and Mayr, A., Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991. 72: 1031-1038.